A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

Yutaka Kuroda, Ryuta Asada, Kazutaka So, Atsushi Yonezawa, Manabu Nankaku, Kumi Mukai, Toshiko Ito-Ihara, Harue Tada, Michio Yamamoto, Toshinori Murayama, Satoshi Morita, Yasuhiko Tabata, Masayuki Yokode, Akira Shimizu, Shuichi Matsuda, Haruhiko Akiyama

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: We evaluated the safety and clinical outcomes of a single local administration of gelatin hydrogel impregnated with recombinant human fibroblast growth factor (rhFGF)-2 for the treatment of the precollapse stage of osteonecrosis of the femoral head (ONFH). Methods: Patients with ONFH (precollapse stage ≤2) received a single local administration of 800 μg of rhFGF-2-impregnated gelatin hydrogel and were followed up for one year. The surgery was performed using a minimally invasive technique involving a 1-cm skin incision, and walking was allowed from day one postoperatively. The primary outcomes included occurrence of adverse events and complications. The secondary outcomes included changes in the Harris hip scores, visual analog scale for pain scores, University of California, Los Angeles (UCLA) activity scores, and radiological images. Results: We included ten patients, of which five experienced 14 adverse events, including one complication from spinal anesthesia. However, patients completely recovered from all adverse events. The mean clinical scores significantly improved by one year postoperatively compared with the pre-operative scores (before vs. after: visual analog score for pain, 21.2 vs. 5.3 mm; UCLA activity score, 5.5 vs. 6.6; Harris hip score, 81.0 vs. 96.9 points). There was only one case of femoral head collapse; however, this occurred in a hip with extensive necrosis. Stage progression and collapse did not occur in the other nine cases. Computed tomography confirmed bone regeneration in the femoral heads. Conclusions: Clinical application of rhFGF-2-impregnated gelatin hydrogel for patients with precollapse ONFH was feasible and safe.

Original languageEnglish
Pages (from-to)1747-1754
Number of pages8
JournalInternational Orthopaedics
Volume40
Issue number8
DOIs
Publication statusPublished - Aug 1 2016
Externally publishedYes

Fingerprint

Osteonecrosis
Fibroblast Growth Factors
Thigh
Hydrogel
Fibroblast Growth Factor 2
Gelatin
Hip
Los Angeles
Therapeutics
Bone Regeneration
Spinal Anesthesia
Pain Measurement
Walking
Necrosis
Tomography
Safety
Pain
Skin

Keywords

  • Clinical trial
  • Femoral head
  • FGF
  • Growth factor
  • Osteonecrosis
  • Regenerative therapy

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. / Kuroda, Yutaka; Asada, Ryuta; So, Kazutaka; Yonezawa, Atsushi; Nankaku, Manabu; Mukai, Kumi; Ito-Ihara, Toshiko; Tada, Harue; Yamamoto, Michio; Murayama, Toshinori; Morita, Satoshi; Tabata, Yasuhiko; Yokode, Masayuki; Shimizu, Akira; Matsuda, Shuichi; Akiyama, Haruhiko.

In: International Orthopaedics, Vol. 40, No. 8, 01.08.2016, p. 1747-1754.

Research output: Contribution to journalArticle

Kuroda, Y, Asada, R, So, K, Yonezawa, A, Nankaku, M, Mukai, K, Ito-Ihara, T, Tada, H, Yamamoto, M, Murayama, T, Morita, S, Tabata, Y, Yokode, M, Shimizu, A, Matsuda, S & Akiyama, H 2016, 'A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head', International Orthopaedics, vol. 40, no. 8, pp. 1747-1754. https://doi.org/10.1007/s00264-015-3083-1
Kuroda, Yutaka ; Asada, Ryuta ; So, Kazutaka ; Yonezawa, Atsushi ; Nankaku, Manabu ; Mukai, Kumi ; Ito-Ihara, Toshiko ; Tada, Harue ; Yamamoto, Michio ; Murayama, Toshinori ; Morita, Satoshi ; Tabata, Yasuhiko ; Yokode, Masayuki ; Shimizu, Akira ; Matsuda, Shuichi ; Akiyama, Haruhiko. / A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. In: International Orthopaedics. 2016 ; Vol. 40, No. 8. pp. 1747-1754.
@article{065837d531f74ae4a72c2ee66968cb98,
title = "A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head",
abstract = "Purpose: We evaluated the safety and clinical outcomes of a single local administration of gelatin hydrogel impregnated with recombinant human fibroblast growth factor (rhFGF)-2 for the treatment of the precollapse stage of osteonecrosis of the femoral head (ONFH). Methods: Patients with ONFH (precollapse stage ≤2) received a single local administration of 800 μg of rhFGF-2-impregnated gelatin hydrogel and were followed up for one year. The surgery was performed using a minimally invasive technique involving a 1-cm skin incision, and walking was allowed from day one postoperatively. The primary outcomes included occurrence of adverse events and complications. The secondary outcomes included changes in the Harris hip scores, visual analog scale for pain scores, University of California, Los Angeles (UCLA) activity scores, and radiological images. Results: We included ten patients, of which five experienced 14 adverse events, including one complication from spinal anesthesia. However, patients completely recovered from all adverse events. The mean clinical scores significantly improved by one year postoperatively compared with the pre-operative scores (before vs. after: visual analog score for pain, 21.2 vs. 5.3 mm; UCLA activity score, 5.5 vs. 6.6; Harris hip score, 81.0 vs. 96.9 points). There was only one case of femoral head collapse; however, this occurred in a hip with extensive necrosis. Stage progression and collapse did not occur in the other nine cases. Computed tomography confirmed bone regeneration in the femoral heads. Conclusions: Clinical application of rhFGF-2-impregnated gelatin hydrogel for patients with precollapse ONFH was feasible and safe.",
keywords = "Clinical trial, Femoral head, FGF, Growth factor, Osteonecrosis, Regenerative therapy",
author = "Yutaka Kuroda and Ryuta Asada and Kazutaka So and Atsushi Yonezawa and Manabu Nankaku and Kumi Mukai and Toshiko Ito-Ihara and Harue Tada and Michio Yamamoto and Toshinori Murayama and Satoshi Morita and Yasuhiko Tabata and Masayuki Yokode and Akira Shimizu and Shuichi Matsuda and Haruhiko Akiyama",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00264-015-3083-1",
language = "English",
volume = "40",
pages = "1747--1754",
journal = "International Orthopaedics",
issn = "0341-2695",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

AU - Kuroda, Yutaka

AU - Asada, Ryuta

AU - So, Kazutaka

AU - Yonezawa, Atsushi

AU - Nankaku, Manabu

AU - Mukai, Kumi

AU - Ito-Ihara, Toshiko

AU - Tada, Harue

AU - Yamamoto, Michio

AU - Murayama, Toshinori

AU - Morita, Satoshi

AU - Tabata, Yasuhiko

AU - Yokode, Masayuki

AU - Shimizu, Akira

AU - Matsuda, Shuichi

AU - Akiyama, Haruhiko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: We evaluated the safety and clinical outcomes of a single local administration of gelatin hydrogel impregnated with recombinant human fibroblast growth factor (rhFGF)-2 for the treatment of the precollapse stage of osteonecrosis of the femoral head (ONFH). Methods: Patients with ONFH (precollapse stage ≤2) received a single local administration of 800 μg of rhFGF-2-impregnated gelatin hydrogel and were followed up for one year. The surgery was performed using a minimally invasive technique involving a 1-cm skin incision, and walking was allowed from day one postoperatively. The primary outcomes included occurrence of adverse events and complications. The secondary outcomes included changes in the Harris hip scores, visual analog scale for pain scores, University of California, Los Angeles (UCLA) activity scores, and radiological images. Results: We included ten patients, of which five experienced 14 adverse events, including one complication from spinal anesthesia. However, patients completely recovered from all adverse events. The mean clinical scores significantly improved by one year postoperatively compared with the pre-operative scores (before vs. after: visual analog score for pain, 21.2 vs. 5.3 mm; UCLA activity score, 5.5 vs. 6.6; Harris hip score, 81.0 vs. 96.9 points). There was only one case of femoral head collapse; however, this occurred in a hip with extensive necrosis. Stage progression and collapse did not occur in the other nine cases. Computed tomography confirmed bone regeneration in the femoral heads. Conclusions: Clinical application of rhFGF-2-impregnated gelatin hydrogel for patients with precollapse ONFH was feasible and safe.

AB - Purpose: We evaluated the safety and clinical outcomes of a single local administration of gelatin hydrogel impregnated with recombinant human fibroblast growth factor (rhFGF)-2 for the treatment of the precollapse stage of osteonecrosis of the femoral head (ONFH). Methods: Patients with ONFH (precollapse stage ≤2) received a single local administration of 800 μg of rhFGF-2-impregnated gelatin hydrogel and were followed up for one year. The surgery was performed using a minimally invasive technique involving a 1-cm skin incision, and walking was allowed from day one postoperatively. The primary outcomes included occurrence of adverse events and complications. The secondary outcomes included changes in the Harris hip scores, visual analog scale for pain scores, University of California, Los Angeles (UCLA) activity scores, and radiological images. Results: We included ten patients, of which five experienced 14 adverse events, including one complication from spinal anesthesia. However, patients completely recovered from all adverse events. The mean clinical scores significantly improved by one year postoperatively compared with the pre-operative scores (before vs. after: visual analog score for pain, 21.2 vs. 5.3 mm; UCLA activity score, 5.5 vs. 6.6; Harris hip score, 81.0 vs. 96.9 points). There was only one case of femoral head collapse; however, this occurred in a hip with extensive necrosis. Stage progression and collapse did not occur in the other nine cases. Computed tomography confirmed bone regeneration in the femoral heads. Conclusions: Clinical application of rhFGF-2-impregnated gelatin hydrogel for patients with precollapse ONFH was feasible and safe.

KW - Clinical trial

KW - Femoral head

KW - FGF

KW - Growth factor

KW - Osteonecrosis

KW - Regenerative therapy

UR - http://www.scopus.com/inward/record.url?scp=84951974919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951974919&partnerID=8YFLogxK

U2 - 10.1007/s00264-015-3083-1

DO - 10.1007/s00264-015-3083-1

M3 - Article

C2 - 26715504

AN - SCOPUS:84951974919

VL - 40

SP - 1747

EP - 1754

JO - International Orthopaedics

JF - International Orthopaedics

SN - 0341-2695

IS - 8

ER -